8-K: SS Innovations Q3 Revenue Soars 192.5% on Robotic System Sales

SS Innovations International, Inc. reported a 192.5% increase in third-quarter 2025 revenue to $12.8 million, driven by strong sales of its SSi Mantra 3 surgical robotic system.

Summary

• Third Quarter 2025 Revenue increased 192.5% year-over-year to $12.8 million from $4.4 million in Q3 2024.
• Third Quarter 2025 Gross profit rose 166.0% to $6.2 million from $2.3 million in Q3 2024.
• Third Quarter 2025 Net loss was $3.7 million, or $(0.02) per diluted share, compared to a net loss of $3.2 million, or $(0.02) per diluted share, in Q3 2024.
• SSi Mantra surgical robotic system installations totaled 27 in Q3 2025, up 350.0% from 6 installations in Q3 2024 and up 17.4% from 23 installations in Q2 2025.
• First Nine Months 2025 Revenue increased 123.0% to $28.0 million from $12.5 million in the first nine months of 2024.
• First Nine Months 2025 Gross profit rose 193.7% to $13.2 million from $4.5 million in the first nine months of 2024.
• First Nine Months 2025 Net loss was $9.7 million, or $(0.05) per diluted share, compared to a net loss of $17.2 million, or $(0.10) per diluted share, in the first nine months of 2024.
• SSi Mantra surgical robotic system installations totaled 63 in the first nine months of 2025, up 152.0% from 25 installations in the first nine months of 2024.
• As of September 30, 2025, cash and cash equivalents totaled $5.7 million, excluding restricted cash, and long-term debt was $0.
• The SSi Mantra cumulative installed base reached 127 systems in seven countries, and cumulative surgeries totaled 6,057, including 56 telesurgeries and 319 cardiac procedures.

Sentiment

Score: 8

Explanation: The company demonstrates very strong revenue and installation growth, significant progress on regulatory approvals for major markets (US, EU), and a reduced net loss for the nine-month period. While Q3 net loss increased slightly and gross margin dipped, the overall trajectory and strategic advancements are highly positive, indicating strong operational momentum and future potential.

Positives

• Revenue increased significantly by 192.5% in Q3 2025 and 123.0% in the first nine months of 2025, demonstrating strong market adoption.
• SSi Mantra surgical robotic system installations grew substantially by 350.0% in Q3 2025 and 152.0% in the first nine months of 2025.
• Gross profit growth outpaced revenue growth for the nine-month period, rising 193.7% compared to a 123.0% revenue increase.
• Gross margin expanded to 47.1% for the first nine months of 2025 from 35.8% in the prior year period.
• Net loss for the first nine months of 2025 significantly reduced to $9.7 million from $17.2 million in the prior year period.
• Successfully completed a human factors validation study at Johns Hopkins Hospital, a critical step for the upcoming FDA 510(k) premarket notification submission.
• Regulatory approval for the SSi Mantra has been secured in seven countries, with active steps being taken to enter the U.S. and European Union markets.
• Achieved milestones including the first robotic telesurgery from a mobile unit and the world's first pediatric pyeloplasty telesurgery using the SSi Mantra system.
• The company reported no long-term debt as of September 30, 2025.

Negatives

• Gross margin slightly decreased in Q3 2025 to 48.1% compared to 52.8% in Q3 2024.
• Net loss increased in Q3 2025 to $3.7 million from $3.2 million in Q3 2024.
• Cash and cash equivalents, excluding restricted cash, totaled $5.7 million as of September 30, 2025, which may be relatively low given ambitious expansion plans.
• Operating expenses, particularly selling, general and administrative expense, increased significantly year-over-year.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied.
• Investors should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors which are, in some cases, beyond the Company's control and could affect actual results.
• Some risks and uncertainties that could cause actual results to differ materially are set forth in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission.

Future Outlook

The company anticipates submitting its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2025 and continues along the pathway towards European Union CE marking certification in the first half of 2026. Management expects continued robust organic growth in existing markets.

Management Comments

• "We delivered strong revenue growth in the third quarter of 2025, driven by higher unit sales of our advanced, cost-effective SSi Mantra 3 surgical robotic system in India and abroad."
• "The SSi Mantras rapidly expanding installed base and increasing utilization reflect its cost advantages, ease of use, differentiated features, and compelling surgical outcomes."
• "We've become a leader in the large and growing India market and remain committed to democratizing access globally to cutting edge surgical robotic care."
• "We now have regulatory approval for the SSi Mantra in seven countries and are taking steps to enter the U.S. and European Union markets."
• "We are making good progress towards important regulatory milestones and remain well positioned for continuing robust organic growth in our existing markets."

Industry Context

SS Innovations is positioning itself as a leader in the rapidly expanding global surgical robotics market, particularly by focusing on affordability and accessibility. Its strong growth in installations and surgeries, especially in India and other international markets, indicates successful penetration in regions where cost-effectiveness is a significant competitive advantage. The pursuit of FDA and CE marking approvals signifies a strategic move to challenge established players in major Western markets, potentially disrupting the current landscape dominated by more expensive systems.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, expanding market presence, and progress towards major regulatory approvals (FDA, CE Mark), which could drive future value. Reduced nine-month net loss is also positive.
• Customers (Hospitals/Surgeons): Increased access to affordable robotic surgical technology, potentially leading to better patient outcomes and operational efficiency.
• Employees: Potential for growth and expansion, possibly leading to increased hiring and career opportunities.
• Creditors: Improved financial performance and strategic advancements could enhance the company's creditworthiness.

Next Steps

• Submit 510(k) premarket notification to the U.S. FDA in the fourth quarter of 2025.
• Continue along the pathway towards European Union CE marking certification in the first half of 2026.
• Participate in the UBS Global Healthcare Conference on November 11, 2025.
• Participate in the Stifel 2025 Healthcare Conference on November 12, 2025, including a group presentation.
• Continue robust organic growth in existing markets.

Key Dates

Recommendation

The company demonstrates exceptional growth in revenue (192.5% YoY in Q3) and system installations (350% YoY in Q3), indicating strong market traction for its cost-effective SSi Mantra surgical robotic system. Significant progress towards FDA 510(k) submission and EU CE marking certification opens up massive new market opportunities. While Q3 net loss increased slightly, the nine-month net loss significantly narrowed, and the overall strategic direction, coupled with successful telesurgery milestones, positions SS Innovations for substantial future expansion and market disruption in the global surgical robotics sector. The current valuation, given the growth trajectory and impending market entries, presents a compelling investment opportunity.

Keywords

Surgical Robotics, SSi Mantra, Medical Devices, Robotic Surgery, Healthcare Technology, FDA Approval, CE Marking, Financial Results, Q3 2025, SS Innovations International